Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to developing life-changing medicines for people with serious diseases, often with limited or no options. The company focuses on areas such as sleep, neurological disorders, hematology, and oncology, including hematologic malignancies and solid tumors. Jazz Pharmaceuticals operates worldwide, with a significant presence in the United States and Europe, and sells its products through a network of local distributors and wholesalers.

The company’s portfolio includes several notable products, such as Xyrem (sodium oxybate), Erwinaze, Defitelio, FazaClo, FazaClo HD, Luvox CR, Prialt, and Vyxeos. These medications address various medical conditions, including sleep disorders, certain cancers, and other serious health issues. Jazz Pharmaceuticals is committed to improving patients’ lives by identifying, developing, and commercializing meaningful products that address unmet medical needs.

In 2011, Jazz Pharmaceuticals merged with Azur Pharma plc, forming Jazz Pharmaceuticals plc. This merger expanded the company’s global footprint and enhanced its capabilities in developing and commercializing pharmaceutical products. The combined company has since continued to grow and diversify its product offerings, focusing on innovative treatments for complex diseases.

Jazz Pharmaceuticals’ mission is to innovate to transform the lives of patients and their families. The company is dedicated to developing life-changing medicines for people with serious diseases, often with limited or no therapeutic options. By transforming biopharmaceutical discoveries into novel medicines, Jazz Pharmaceuticals aims to give people around the world the opportunity to redefine what’s possible.

The company’s vision includes generating $5 billion in revenue by 2025 and the approval of at least five novel products by the end of the decade. To achieve this, Jazz Pharmaceuticals focuses on delivering sustainable growth and enhancing value, driving the continued transformation of the company into an innovative, high-growth global biopharmaceutical leader, and improving adjusted operating margin by 5% from 2021 to 2025.